December 02, 2025 a 08:38 am
REGN: Analysts Ratings - Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. presents an intriguing investment opportunity, given its focus on pharmaceuticals targeting diverse therapeutic areas. The analysis of recent analyst ratings highlights a consistent cautious optimism in the stock's performance. Despite slight shifts in sentiment, the balance of recommendations suggests stability, but investors should remain mindful of emerging sentiment trends and external business factors.
Historical Stock Grades
| Rating Category | Number of Ratings | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 16 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, the sentiment around Regeneron Pharmaceuticals exhibits dynamic shifts. The number of "Strong Buy" recommendations has decreased from 7 to 3, indicating a pullback in bullish confidence. Conversely, "Buy" remains robust, stabilizing any potential negative momentum. Observations:
- Overall analyst ratings have seen fluctuations but have stabilized towards the year's end.
- Decline in "Strong Buy" suggests heightened caution among analysts.
- "Hold" ratings witnessing a mild increase, signaling a conservative approach.
Percentage Trends
The analyst rating proportions show varying trends throughout the examined period. The reduction in "Strong Buy" ratings reflects a shifting sentiment towards more conservative stances. This can be attributed to a wider industry context or company-specific developments. Key points:
- The percentage of "Buy" ratings remains relatively steady at approximately 50% over several months.
- "Strong Buy" ratings show a significant drop, from approximately 20% to 10%.
- Increase in "Hold" recommendations from about 30% to 35% suggests a more cautious market outlook.
- The stabilization of "Buy" despite a decrease in "Strong Buy" indicates continued confidence, albeit more measured.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-24 | Sector Perform | Sector Perform | Scotiabank |
| 2025-11-20 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-11-07 | Neutral | Neutral | UBS |
| 2025-10-29 | Buy | Buy | Guggenheim |
| 2025-10-29 | Underperform | Underperform | B of A Securities |
Analyst Recommendations with Change of Opinion
In the past months, there have been several noteworthy shifts in analyst opinions on Regeneron. Such changes reflect the broader market's evolving perspectives and internal corporate developments. Tables show recent changes:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-30 | Equal Weight | Overweight | Wells Fargo |
| 2025-05-14 | Buy | Neutral | Citigroup |
| 2025-02-05 | Outperform | Market Perform | Leerink Partners |
| 2025-01-16 | Neutral | Buy | UBS |
| 2024-09-24 | Market Perform | Outperform | Leerink Partners |
Interpretation
The analysis of Regeneron's ratings and recommendations encapsulates a nuanced picture. The reductions in "Strong Buy" suggest a tempered enthusiasm, balanced by resilience in "Buy" ratings. Without significant movements toward "Sell," the sentiment infers cautious optimism. While reduced "Strong Buys" could signal market apprehension, the overall stability hints at confidence in Regeneron's long-term viability. Nevertheless, close monitoring of sentiment shifts remains vital to gauge future market responses accurately.
Conclusion
Regeneron Pharmaceuticals stands at an interesting juncture, with a stable base of "Buy" ratings complemented by a cautious reduction in "Strong Buy" endorsements. This shift hints at potential uncertainties, perhaps from macroeconomic variables or industry-specific challenges. Nonetheless, the steadfast percentage of "Buy" ratings underscores enduring analyst confidence. While investors should heed subtle cautionary indicators, the present sentiment provides an optimistic outlook, especially for those with a long-term investment horizon.